"Janus Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit JANUS KINASES.
| Descriptor ID |
D000075242
|
| MeSH Number(s) |
D27.505.519.389.755.500
|
| Concept/Terms |
Janus Kinase Inhibitors- Janus Kinase Inhibitors
- Inhibitors, Janus Kinase
- Kinase Inhibitors, Janus
- JAK Inhibitors
- Inhibitors, JAK
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase Inhibitors".
This graph shows the total number of publications written about "Janus Kinase Inhibitors" by people in this website by year, and whether "Janus Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 2 | 6 |
| 2021 | 3 | 1 | 4 |
| 2022 | 8 | 2 | 10 |
| 2023 | 12 | 0 | 12 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase Inhibitors" by people in Profiles.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.
-
(Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review. Clin Microbiol Infect. 2024 Aug; 30(8):989-998.
-
Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024 May; 11(5):e383-e389.
-
Management of Patients with Early Myelofibrosis: A Discussion of Best Practices. Curr Hematol Malig Rep. 2024 06; 19(3):111-119.
-
JAK/STAT defects and immune dysregulation, and guiding therapeutic choices. Immunol Rev. 2024 Mar; 322(1):311-328.
-
How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits. Curr Rheumatol Rep. 2023 12; 25(12):295-306.
-
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024 02; 59(2):196-202.
-
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
-
New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL /BCL-2 inhibition with navitoclax. Cancer. 2023 11 15; 129(22):3535-3545.
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023 Sep; 10(9):e735-e746.